The latest price target for Coya Therapeutics (NASDAQ:COYA) was reported by Chardan Capital on February 6, 2025. The analyst firm set a price target for $14.00 expecting COYA to rise to within 12 months (a possible 118.75% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Coya Therapeutics (NASDAQ:COYA) was provided by Chardan Capital, and Coya Therapeutics maintained their buy rating.

There is no last upgrade for Coya Therapeutics

There is no last downgrade for Coya Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Coya Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Coya Therapeutics was filed on February 6, 2025 so you should expect the next rating to be made available sometime around February 6, 2026.

While ratings are subjective and will change, the latest Coya Therapeutics (COYA) rating was a maintained with a price target of $14.00 to $14.00. The current price Coya Therapeutics (COYA) is trading at is $6.40, which is out of the analyst’s predicted range.